First Tracks Raises $200M in Private Placement at $32.75/Share
TRAX has more than doubled off its 52-week low of $14.72 on elevated volume (1.9× avg).
Summary
First Tracks Biotherapeutics agreed to sell 6.1 million shares at $32.75 for about $200 million gross in a private placement to institutional investors, with closing expected October 19 and a resale registration statement due within 30 days.
Key Events · Financing and Capital Events · TRAX
-
Private Placement of 6.1M Shares
A securities purchase agreement signed October 15, 2026 covers 6,106,870 shares at $32.75 per share, roughly $200 million gross before placement agent fees and expenses.
-
Dilution of About 17%
The new shares equal approximately 17% of the 35,909,814 shares outstanding as of October 12, 2026 (6,106,870 / 35,909,814).
-
Closing Expected October 19
Closing is subject to customary conditions, including a minimum $110 million aggregate gross proceeds threshold and delivery of lock-up agreements from directors and officers.
-
Resale Registration Due in 30 Days
A registration rights agreement requires filing a resale registration statement within 30 days of closing, with liquidated damages of 1.0% per 30-day period capped at 5.0% of each investor's purchase price for missed deadlines.
Analysis · TRAX · Life Sciences
First Tracks is issuing 6,106,870 new shares at $32.75 for roughly $200 million gross, a substantial capital raise that funds clinical development of ANB033 and extends the runway well beyond the $168 million cash reported with Q2 results. The price sits below today's $36.50 quote, but the deal was struck with a broad group of institutional and mutual fund investors, and the company secured lock-up agreements from all directors and officers plus a 45-day standstill on further equity issuance. The trade-off is dilution: the new shares equal about 17% of the 35.9 million shares outstanding as of October 12, and the resale registration statement due within 30 days of closing will make that overhang tradable. Closing is expected October 19, 2026, subject to customary conditions.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRAX was trading at $36.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $14.72 to $49.91. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.